 |
| Multiple Myeloma |
“Geraldine Ferraro was a true trailblazer, an inspiration to many, an incredible advocate for cancer research, and a very dear friend. She will be sadly missed, never far from our hearts, and fondly remembered for her incredible legacy and the extraordinary woman who she was. We pray that her family finds comfort and peace during this sorrowful time,” said Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation, and a patient with multiple myeloma.
In addition to serving on the MMRF’s Honorary Board of Directors, Ferraro was actively involved in the Foundation’s work to bring new treatments to patients. In 2002, she passionately testified before Congress for the critical need for increased research funding, and a year later, a bill was signed authorizing $250 million for blood cancer research. Congress then appropriated $5 million to the Geraldine Ferraro Blood Cancer Education Program in 2003 and renewed funding in 2006, enabling the MMRF to provide high-quality educational programs to underserved populations.
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $160 million since its inception to fund more than 130 laboratories worldwide. An outstanding 89% of funds raised go toward research and related programming. The MMRF has supported 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 30 clinical trials through its sister organization, the MMRC.
Sources: http://www.businesswire.com
